- Home
- CZNC vs PRQR Comparison
CZNC vs PRQR Comparison
Compare CZNC & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CZNC
- PRQR
- Stock Information
- Founded
- CZNC 1864
- PRQR 2012
- Country
- CZNC United States
- PRQR Netherlands
- Employees
- CZNC N/A
- PRQR N/A
- Industry
- CZNC Major Banks
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- CZNC Finance
- PRQR Health Care
- Exchange
- CZNC Nasdaq
- PRQR Nasdaq
- Market Cap
- CZNC 315.7M
- PRQR 309.5M
- IPO Year
- CZNC N/A
- PRQR 2014
- Fundamental
- Price
- CZNC $20.70
- PRQR $3.50
- Analyst Decision
- CZNC
- PRQR Strong Buy
- Analyst Count
- CZNC 0
- PRQR 4
- Target Price
- CZNC N/A
- PRQR $7.13
- AVG Volume (30 Days)
- CZNC 33.0K
- PRQR 534.3K
- Earning Date
- CZNC 10-17-2024
- PRQR 11-07-2024
- Dividend Yield
- CZNC 5.48%
- PRQR N/A
- EPS Growth
- CZNC N/A
- PRQR N/A
- EPS
- CZNC 1.44
- PRQR N/A
- Revenue
- CZNC $101,899,000.00
- PRQR $20,506,357.00
- Revenue This Year
- CZNC N/A
- PRQR $370.31
- Revenue Next Year
- CZNC $6.19
- PRQR N/A
- P/E Ratio
- CZNC $14.23
- PRQR N/A
- Revenue Growth
- CZNC N/A
- PRQR 306.68
- 52 Week Low
- CZNC $16.50
- PRQR $1.61
- 52 Week High
- CZNC $23.50
- PRQR $4.62
- Technical
- Relative Strength Index (RSI)
- CZNC 58.31
- PRQR 48.63
- Support Level
- CZNC $20.02
- PRQR $3.46
- Resistance Level
- CZNC $20.80
- PRQR $3.97
- Average True Range (ATR)
- CZNC 0.44
- PRQR 0.19
- MACD
- CZNC 0.01
- PRQR -0.06
- Stochastic Oscillator
- CZNC 77.78
- PRQR 17.81
About CZNC Citizens & Northern Corp
Citizens & Northern Corp is a community bank operating through its subsidiaries. It provides banking services, including deposit and loan products for personal and commercial customers. The bank also maintains a trust division that provides a wide range of financial services, such as 401(k) plans, retirement planning, estate planning, estate settlements and asset management.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceuticals company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.